2310030G06Rik Inhibitors
Chemical inhibitors of 2310030G06Rik have been identified to functionally inhibit the protein's activity through various signaling pathways. Rapamycin directly targets the mTOR pathway, which is central to cellular processes that 2310030G06Rik may be involved in, such as cell growth and proliferation, leading to the protein's functional inhibition. Similarly, PP242, as a selective mTOR inhibitor, disrupts the same pathway, achieving a similar outcome. Compounds like LY294002 and Wortmannin, both potent PI3K inhibitors, interrupt the PI3K/Akt pathway, a crucial signaling cascade that, when inhibited, would affect the activity of 2310030G06Rik. ZSTK474, also a PI3K inhibitor, operates within the same pathway, effectively leading to the protein's functional inhibition.
Inhibitors targeting the MAPK pathway also play a role in modulating 2310030G06Rik's activity. U0126 and PD98059, both MEK inhibitors, prevent the activation of ERK, a protein downstream of MEK in the MAPK pathway. By doing so, they impede the signaling that may regulate 2310030G06Rik's function. SB203580 and SP600125, which inhibit p38 MAPK and JNK respectively, would also alter the protein's activity by targeting these specific kinases involved in the MAPK pathway. Dasatinib, which targets Src family kinases, and Imatinib, which inhibits the BCR-ABL tyrosine kinase, would lead to the functional inhibition of 2310030G06Rik by obstructing the signaling pathways that these kinases regulate. Sorafenib, a Raf kinase inhibitor, disrupts yet another aspect of the MAPK pathway, further illustrating the diverse yet specific mechanisms by which these chemical inhibitors modulate the activity of 2310030G06Rik.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin directly inhibits the mTOR pathway, which could be crucial for 2310030G06Rik's activity if the protein is involved in cell growth and proliferation, thereby functionally inhibiting the protein. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, and by disrupting the PI3K/Akt pathway, it would functionally inhibit 2310030G06Rik if the protein is regulated by this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 inhibits MEK1/2, key components of the MAPK pathway. This action would lead to a functional inhibition of 2310030G06Rik if the protein operates within this signaling cascade. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 targets p38 MAPK, and inhibition of this kinase would result in functional inhibition of 2310030G06Rik if it is modulated by p38 MAPK signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that would prevent ERK activation in the MAPK pathway, leading to functional inhibition of 2310030G06Rik if the protein is part of this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. Inhibition of JNK would functionally inhibit 2310030G06Rik if it is involved in JNK-mediated signaling processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, another PI3K inhibitor, would functionally inhibit 2310030G06Rik by disrupting the PI3K/Akt pathway, presuming that the protein's activity is contingent on this signaling pathway. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
PP242 is an mTOR inhibitor that would result in the functional inhibition of 2310030G06Rik by impeding mTOR signaling, which may be imperative for the protein's function. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib inhibits Src family kinases and would functionally inhibit 2310030G06Rik by blocking Src kinase signaling pathways that regulate the protein's activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib targets BCR-ABL tyrosine kinase and would functionally inhibit 2310030G06Rik by impeding pathways involving BCR-ABL that may control the protein's function. | ||||||